Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
Welcome to the 16th issue of the AMYPAD newsletter
Welcome to the 16th issue of the AMYPAD newsletter 25 Feb 2021 We are writing to you with the latest news from the AMYPAD project......
AMYPAD goals for 2021
AMYPAD goals for 2021 25 Feb 2021 We have conducted a series of video interviews with 7 AMYPAD members......
Interview with Andrew Stephens
Interview with Andrew Stephens 24 Feb 2021 I am the Chief Medical Officer for Life Molecular Imaging. LMI is providing florbetaben for amyloid imaging to AMYPAD along with flutemetamol from GE Healthcare....
Recruitment status (as 29 January, 2021)
Recruitment status (as 29 January, 2021)

AMYPAD recruitment update January 2021